Three-year experience with alendronate treatment in postmenopausal osteoporotic japanese women with or without renal dysfunction: A retrospective study

Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

2 Citations (Scopus)


Background and Objective: Chronic kidney disease is associated with an increased risk of fragility fractures. A retrospective study was conducted to compare outcomes after 3 years of alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction (RD). Methods: One hundred and thirty-five postmenopausal osteoporotic Japanese women (mean age at baseline: 68 years) who had been treated with alendronate in our outpatient clinic for more than 3 years were analysed. The lumbar spine bone mineral density (BMD) of patients was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Twenty-six women had RD with an estimated glomerular filtration rate (eGFR) of 60mL/min/1.73m2. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, in a manner that was similar among women with or without RD. However, the incidence of non-vertebral fractures, but not that of vertebral fractures, was significantly higher among women with RD than among women without RD. Conclusions: Alendronate treatment appeared to have a similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without RD. However, further studies are needed to confirm that RD may increase the risk of non-vertebral fractures in patients treated with alendronate.

Original languageEnglish
Pages (from-to)133-142
Number of pages10
JournalDrugs and Aging
Issue number2
Publication statusPublished - 2012



  • Alendronic-acid
  • Elderly
  • Kidney-disorders
  • Postmenopausal-osteoporosis.

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Cite this